BioSpace News Archive

Verrica Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration accepted for filing the Company’s resubmitted New Drug Application for VP-102 for the treatment of molluscum contagiosum and assigned a Prescription Drug User Fee Act goal date of July 23, 2023.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical products, announced financial results for the quarter ended December 31, 2022.

Adverum Biotechnologies, Inc. announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States.

Adial Pharmaceuticals, Inc. announced the closing of its previously announced at-the-market registered direct offering of 1,829,269 shares of common stock at a purchase price of $0.41 per share of common stock with a single institutional investor for gross proceeds of $0.75 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company.

At SLAS 2023, SCIEX, a global leader in life science analytical technologies, announces a new collaboration with HighRes Biosolutions, a leading global laboratory automation company.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced positive results from the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.

ZyVersa Therapeutics, Inc. announced that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.